STATs: An old story, yet mesmerizing

Cell Journal

Volumn 17, Issue 3, 2015, Pages 395-411

  Abroun, Saeid ^a   Saki, Najmaldin ^b   Ahmadvand, Mohammad ^a   Asghari, Farahnaz ^c   Salari, Fatemeh ^b   Rahim, Fakher ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

JAK; Malignancy; MiRNA; Signaling Pathways; STAT

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; JANUS KINASE; MICRORNA; NAVELBINE; PACLITAXEL; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN TYROSINE PHOSPHATASE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING;

ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CONFORMATIONAL TRANSITION; CYTOPLASM; DIMERIZATION; HELPER CELL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MYELOID PROGENITOR CELL; NONHUMAN; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

EID: 84943389897     PISSN: 22285806     EISSN: 22285814     Source Type: Journal    
DOI: None     Document Type: Article

References (121)

1. Fu XY, Schindler C, Improta T, Aebersold R, Darnell JE Jr. The proteins of ISGF-3, the interferon alpha-induced tran-scriptional activator, defne a gene family involved in signal transduction. Proc Natl Acad Sci USA. 1992; 89(16): 7840-7843.
2. Schindler C, Fu X Y, Improta T, Aebersold R, Darnell JE Jr. Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci USA. 1992; 89(16): 7836-7839.
3. Schindler C, Shuai K, Prezioso VR, Darnell JE Jr. Inter-feron-dependent tyrosine phosphorylation of a latent cy-toplasmic transcription factor. Science. 1992; 257(5071): 809-813.
4. Darnell JE Jr. STATs and gene regulation. Science. 1997; 277(5332): 1630-1635.
5. Ishikawa H, Mahmoud MS, Fujii R, Abroun S, Kawano MM. Proliferation of immature myeloma cells by interleu-kin-6 is associated with CD45 expression in human multiple myeloma. Leuk Lymphoma. 2000; 39(1-2): 51-55.
6. Chatterjee-Kishore M, van den Akker F, Stark GR. Association of STATs with relatives and friends. Trends Cell Biol. 2000; 10(3): 106-111.
7. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999; 98(3): 295-303.
8. Williams JG. STAT signalling in cell proliferation and in development. Curr Opin Genet Dev. 2000; 10(5): 503-507.
9. Bowman T, Garcia R, Turkson J, Jove R. STATs in onco-genesis. Oncogene. 2000; 19(21): 2474-2488.
10. Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002; 109(9): 1139-1142.
11. Bromberg JF. Activation of STAT proteins and growth control. Bioessays. 2001; 23(2): 161-169.
12. Krolewski JJ, Lee R, Eddy R, Shows TB, Dalla-Favera R. Identifcation and chromosomal mapping of new human tyrosine kinase genes. Oncogene. 1990; 5(3): 277-282.
13. Lai KS, Jin Y, Graham DK, Witthuhn BA, Ihle JN, Liu ET. A kinase-defcient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. J Biol Chem. 1995; 270(42): 25028-25036.
14. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002; 3(9): 651-662.
15. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA. 1997; 94(8): 3801-3804.
16. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002; 285(1-2): 1-24.
17. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA. 2000; 97(8): 4227-4232.
18. Leung S, Qureshi SA, Kerr IM, Darnell JE Jr, Stark GR. Role of STAT2 in the alpha interferon signaling pathway. Mol Cell Biol. 1995; 15(3): 1312-1317.
19. Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E, Smith PD. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol. 2001; 19(6): 1155-1160.
20. Quadros MR, Peruzzi F, Kari C, Rodeck U. Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res. 2004; 64(11): 3934-3939.
21. Chung J, Uchida E, Grammer TC, Blenis J. STAT3 ser-ine phosphorylation by ERK-dependent and-independent pathways negatively modulates its tyrosine phosphoryla-tion. Mol Cell Biol. 1997; 17(11): 6508-6516.
22. Chen Y, Wen R, Yang S, Schuman J, Zhang EE, Yi T, et al. Identifcation of Shp-2 as a Stat5A phosphatase. J Biol Chem. 2003; 278(19): 16520-16527.
23. Denson LA, Held MA, Menon RK, Frank SJ, Parlow AF, Arnold DL. Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3. Am J Physiol Gastrointest Liver Physiol. 2003; 284(4): G646-654.
24. Boyle K, Zhang JG, Nicholson SE, Trounson E, Babon JJ, McManus EJ, et al. Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation. Cell Signal. 2009; 21(3): 394-404.
25. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009; 6(10): 587-595.
26. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000; 19(49): 5662-5679.
27. Abroun S, Saki N. Cellular and molecular aspects of Multiple Myeloma. Sci J Blood Transfus Org. 2010; 7(3): 183-195.
28. Fielding CA, McLoughlin RM, McLeod L, Colmont CS, Najdovska M, Grail D, et al. IL-6 regulates neutrophil traf-fcking during acute infammation via STAT3. J Immunol. 2008; 181(3): 2189-2195.
29. Yu JH, Kim KH, Kim H. Suppression of IL-1beta expression by the Jak 2 inhibitor AG490 in cerulein-stimulated pancreatic acinar cells. Biochem Pharmacol. 2006; 72(11): 1555-1562.
30. Yu Z, Zhang W, Kone BC. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J. 2002; 367(Pt 1): 97-105.
31. Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature. 1998; 394(6689): 145-151.
32. Woetmann A, Nielsen M, Christensen ST, Brockdorff J, Kaltoft K, Engel AM, et al. Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci USA. 1999; 96(19): 10620-10625.
33. Akira S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells. 1999; 17(3): 138-146.
34. Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Trans-duct Res. 1999; 19(1-4): 75-120.
35. Niwa H, Burdon T, Chambers I, Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998; 12(13): 2048-2060.
36. Matsuda T, Nakamura T, Nakao K, Arai T, Katsuki M, Heike T, et al. STAT3 activation is suffcient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 1999; 18(15): 4261-4269.
37. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10(1): 105-115.
38. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem. 1999; 274(32): 22165-22169.
39. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/-mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999; 98(2): 181-191.
40. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, et al. STAT3 regulates cytokine-mediat-ed generation of infammatory helper T cells. J Biol Chem. 2007; 282(13): 9358-9363.
41. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cy-tokine Growth Factor Rev. 2010; 21(1): 11-19.
42. Reich NC. STAT3 revs up the powerhouse. Sci Signal. 2009; 2(90): pe61.
43. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, et al. Defciency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008; 205(7): 1551-1557.
44. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008; 452(7188): 773-776.
45. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood. 2006; 108(1): 253-261.
46. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA. 1990; 87(18): 6934-6938.
47. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell defciency, and impaired neu-trophil mobilization. Blood. 1994; 84(6): 1737-1746.
48. Tian SS, Lamb P, Seidel HM, Stein RB, Rosen J. Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor. Blood. 1994; 84(6): 1760-1764.
49. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshau-er U, Klingmuller U, Nakajima K, et al. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregu-lation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene. 1999; 18(25): 3742-3753.
50. de Koning JP, Soede-Bobok AA, Ward AC, Schelen AM, Antonissen C, van Leeuwen D, et al. STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cy-clin-dependent kinase inhibitor p27(Kip1). Oncogene. 2000; 19(29): 3290-3298.
51. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA. 1998; 95(18): 10626-10631.
52. Baumann H, Morella KK, White DW, Dembski M, Bailon PS, Kim H, et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci USA. 1996; 93(16): 8374-8378.
53. Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res. 2004; 59: 305-331.
54. Vaghef N, Abroun S, Kaviani S, Alimoghadam K, Rostami Sh, Sadeghi B, et al. The role of leptin in pathophysiology of myeloma cells. Cell J. 2010; 12(3): 319-328.
55. Shimizu H, Inoue K, Mori M. The leptin-dependent and-independent melanocortin signaling system: regulation of feeding and energy expenditure. J Endocrinol. 2007; 193(1): 1-9.
56. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 1995; 267(5206): 1990-1994.
57. Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Taniguchi O, et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleu-kin-6. Blood. 2002; 99(6): 2172-2178.
58. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 2004; 64(10): 3550-3558.
59. Lopez-Perez M, Salazar E P. A role for the cytoskeleton in STAT5 activation in MCF7 human breast cancer cells stimulated with EGF. Int J Biochem Cell Biol. 2006; 38(10): 1716-1728.
60. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, et al. Stat3 regulates microtubules by antagonizing the depo-lymerization activity of stathmin. J Cell Biol. 2006; 172(2): 245-257.
61. Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A, et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. 2009; 7(6): 966-976.
62. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000; 19(21): 2548-2556.
63. Levy DE, Lee CK. What does Stat3 do?. J Clin Invest. 2002; 109(9): 1143-1148.
64. Walker SR, Chaudhury M, Nelson EA, Frank DA. Micro-tubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol. 2010; 78(5): 903-908.
65. Abroun S, Ishikawa H, Tsuyama N, Liu S, Li FJ, Otsuy-ama K, et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected]. Blood. 2004; 103(6): 2291-2298.
66. Leu JI, Crissey MA, Leu J P, Ciliberto G, Taub R. Inter-leukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury. Mol Cell Biol. 2001; 21(2): 414-424.
67. Haga S, Terui K, Zhang HQ, Enosawa S, Ogawa W, Inoue H, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and-independent mechanisms. J Clin Invest. 2003; 112(7): 989-998.
68. Kovalovich K, Li W, DeAngelis R, Greenbaum LE, Ciliber-to G, Taub R. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J Biol Chem. 2001; 276(28): 26605-26613.
69. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest. 2003; 112(7): 978-980.
70. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res. 2006; 12(1): 20-28.
71. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkap-paB. Genes Dev. 2007; 21(11): 1396-1408.
72. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Ca-cho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001; 20(20): 2499-2513.
73. Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol. 2000; 79(1): 67-73.
74. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer. 1999; 83(4): 564-570.
75. Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Otsuy-ama K, et al. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation. Leuk Lymphoma. 2003; 44(9): 1477-1481.
76. Pedranzini L, Leitch A, Bromberg J. Stat3 is required for the development of skin cancer. J Clin Invest. 2004; 114(5): 619-622.
77. Levy O, Granot Y. Arginine-vasopressin activates the JAK-STAT pathway in vascular smooth muscle cells. J Biol Chem. 2006; 281(23): 15597-15604.
78. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007; 178(5): 2623-2629.
79. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mi-togenesis. Proc Natl Acad Sci USA. 2001; 98(13): 7319-7324.
80. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001; 107(3): 351-362.
81. Matsui T, Kinoshita T, Hirano T, Yokota T, Miyajima A. STAT3 down-regulates the expression of cyclin D during liver development. J Biol Chem. 2002; 277(39): 36167-36173.
82. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia. 2005; 19(4): 513-523.
83. Bartoli M, Platt D, Lemtalsi T, Gu X, Brooks SE, Marrero MB, et al. VEGF differentially activates STAT3 in micro-vascular endothelial cells. FASEB J. 2003; 17(11): 1562-1564.
84. Laird AD, Li G, Moss KG, Blake RA, Broome MA, Cher-rington JM, et al. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and-independent growth of human tumor cells. Mol Cancer Ther. 2003; 2(5): 461-469.
85. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21(13): 2000-2008.
86. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003; 22(10): 1517-1527.
87. Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, Hanakawa Y, et al. Nuclear translocation of phospho-rylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem. 2003; 278(41): 40026-40031.
88. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci. 2011; 1215: 150-160.
89. Yu LF, Chen Y, Qiao MM, Zhang YP, Wu YL. The impact of decreased Stat3 activation on 5-fuorouracil resistance of human gastric cancer cell line. Zhonghua Nei Ke Za Zhi. 2004; 43(12): 903-906.
90. Erenoglu C, Akin ML, Uluutku H, Tezcan L, Yildirim S, Batkin A. Angiogenesis predicts poor prognosis in gastric carcinoma. Dig Surg. 2000; 17(6): 581-586.
91. Lu M, Jiang Y, Wang R. The relationship of vascular en-dothelial growth factor and angiogenesis to the progression of gastric carcinoma. Zhonghua Bing Li Xue Za Zhi. 1998; 27(4): 278-281.
92. Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, et al. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 2000; 128(3): 408-416.
93. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smith-gall T, et al. Constitutive activation of Stat3 in fbroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997; 8(12): 1267-1276.
94. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest. 1998; 102(7): 1385-1392.
95. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol. 1999; 11(6): 490-496.
96. Cattaneo E, Magrassi L, De-Fraja C, Conti L, Di Gennaro I, Butti G, et al. Variations in the levels of the JAK/STAT and ShcA proteins in human brain tumors. Anticancer Res. 1998; 18(4A): 2381-2387.
97. Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO, et al. CD5 promotes IL-10 production in chronic lym-phocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol. 2011; 186(8): 4835-4844.
98. Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, et al. STAT-3 activates NF-kappaB in chronic lympho-cytic leukemia cells. Mol Cancer Res. 2011; 9(4): 507-515.
99. Allen JC, Talab F, Zuzel M, Lin K, Slupsky JR. c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells. Blood. 2011; 117(8): 2414-2422.
100. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011; 25(3): 538-550.
101. Ishdorj G, Johnston JB, Gibson SB. Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Mol Cancer Ther. 2010; 9(12): 3302-3314.
102. Ashizawa T, Miyata H, Ishii H, Oshita C, Matsuno K, Mas-uda Y, et al. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol. 2011; 38(5): 1245-1252.
103. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specifc Stat3-defcient mice. J Immunol. 1998; 161(9): 4652-4660.
104. Kawano MM, Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, et al. Growth mechanism of human myeloma cells by interleukin-6. Int J Hematol. 2002; 76 Suppl 1: 329-333.
105. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 2004; 114(5): 720-728.
106. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004; 4(2): 97-105.
107. van der Fits L, van Kester MS, Qin Y, Out-Luiting JJ, Smit F, Zoutman WH, et al. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sezary syndrome. J Invest Dermatol. 2011; 131(3): 762-768.
108. Zhu Y, Yu X, Fu H, Wang H, Wang P, Zheng X, et al. Mi-croRNA-21 is involved in ionizing radiation-promoted liver carcinogenesis. Int J Clin Exp Med. 2010; 3(3): 211-222.
109. Yang CH, Yue J, Fan M, Pfeffer LM. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res. 2010; 70(20): 8108-8116.
110. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking infammation to cancer. Mol Cell. 2010; 39(4): 493-506.
111. Shen XH, Han YJ, Zhang DX, Cui XS, Kim NH. A link between the interleukin-6/Stat3 anti-apoptotic pathway and microRNA-21 in preimplantation mouse embryos. Mol Re-prod Dev. 2009; 76(9): 854-862.
112. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010; 70(8): 3119-3127.
113. McCoy CE, Sheedy FJ, Qualls JE, Doyle SL, Quinn SR, Murray PJ, et al. IL-10 inhibits miR-155 induction by tolllike receptors. J Biol Chem. 2010; 285(27): 20492-20498.
114. Haider KH, Idris NM, Kim HW, Ahmed RP, Shujia J, Ashraf M. MicroRNA-21 is a key determinant in IL-11/Stat3 anti-apoptotic signalling pathway in preconditioning of skeletal myoblasts. Cardiovasc Res. 2010; 88(1): 168-178.
115. Cascio S, DAndrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V, et al. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol. 2010; 224(1): 242-249.
116. Carraro G, El-Hashash A, Guidolin D, Tiozzo C, Turcatel G, Young BM, et al. miR-17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-Cadherin distribution. Dev Biol. 2009; 333(2): 238-250.
117. Surdziel E, Cabanski M, Dallmann I, Lyszkiewicz M, Krue-ger A, Ganser A, et al. Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways. Blood. 2011; 117(16): 4338-4348.
118. Foshay KM, Gallicano GI. miR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation. Dev Biol. 2009; 326(2): 431-443.
119. Kim TM, Huang W, Park R, Park PJ, Johnson MD. A developmental taxonomy of glioblastoma defned and maintained by microRNAs. Cancer Res. 2011; 71(9): 3387-3399.
120. Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, et al. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res. 2011; 71(7): 2611-2621.
121. Haghikia A, Missol-Kolka E, Tsikas D, Venturini L, Brund-iers S, Castoldi M, et al. Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. Eur Heart J. 2011; 32(10): 1287-1297.